Plain-English translation of NCT06358625 on ClinicalTrials.gov ↗ · Source last updated ·
This study is looking for early warning signs that could predict which women with HER2-positive breast cancer are more likely to develop cancer spreading to the brain. Researchers will follow patients over time, take blood samples to look for cancer markers, and carefully monitor for any signs of brain involvement. The goal is to find a way to identify high-risk patients early so they can receive closer monitoring and newer treatments like tucatinib or T-Dxd before brain metastases become a serious problem.
Right now, doctors don't have a reliable way to predict which HER2-positive breast cancer patients will develop brain metastases, and international guidelines don't recommend routine brain screening unless patients have symptoms. However, newer anti-HER2 medications have shown promise in treating brain metastases if caught early, so identifying which patients are at highest risk could change how doctors monitor and treat this disease.
You likely qualify if…
You likely don't qualify if…
You will have an initial assessment visit, then return for regular follow-up appointments to monitor how you're doing and check for any signs of cancer returning to the brain. At these visits, you'll have blood drawn to test for circulating tumor markers that might indicate risk. This ongoing monitoring allows doctors to track your health over time and identify patterns that help predict who is most likely to develop brain metastases.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
France